First Trust Nasdaq Pharmaceuticals ETF
Latest First Trust Nasdaq Pharmaceuticals ETF News and Updates

Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

Pfizer’s Vaccines: A Look at Their Market Performance
In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

Allergan’s Q3 2018 Earnings: Analysts’ Estimates
Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

Wall Street Analysts’ Recommendations for JNJ in January 2018
Wall Street analysts expect Johnson & Johnson to generate EPS of $2.01 on revenues of ~$19.4 billion in 1Q18 for 9.2% growth in revenues compared to 1Q17.

Pfizer’s 4Q17 Estimates: Products with Lower Sales
In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.

Wall Street Recommendations for Mylan in January 2018
As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.

Eli Lilly’s New Products Portfolio in 3Q17
Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17
In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

Bristol-Myers Squibb’s Valuations after Its 3Q17 Earnings
Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”

Bristol-Myers Squibb’s Immunoscience Products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

These Pfizer’s Products Are Now Losing Market Share
Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.

Behind Merck’s Animal Health Segment Performance in 2Q17
Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.

What to Expect from Pfizer’s Biosimilars Business
In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.

Performance of Eli Lilly’s Business Segments in 2Q17
The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.

Major Developments for Johnson & Johnson in 2Q17
Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]

Pfizer’s Valuation after 2Q17 Earnings
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

Johnson & Johnson’s Revenue Trend in 3Q16
In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.

Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment
Opdivo is a human PD-1 blocking antibody used in lung cancer and melanoma treatments. Opdivo is part of BMY’s alliance with Ono Pharmaceutical.

Good News: Johnson & Johnson’s 3Q16 Revenues Expected to Rise
Analysts expect Johnson & Johnson’s (JNJ) 3Q16 revenues to rise 3.7% to $17.7 billion. The expectation comes on the back of an increase in sales of its blockbuster drugs.